(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 12.26% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Grail's revenue in 2025 is $134,285,000.On average, 1 Wall Street analysts forecast GRAL's revenue for 2025 to be $5,197,732,138, with the lowest GRAL revenue forecast at $5,197,732,138, and the highest GRAL revenue forecast at $5,197,732,138. On average, 1 Wall Street analysts forecast GRAL's revenue for 2026 to be $6,072,359,885, with the lowest GRAL revenue forecast at $6,072,359,885, and the highest GRAL revenue forecast at $6,072,359,885.
In 2027, GRAL is forecast to generate $7,030,582,478 in revenue, with the lowest revenue forecast at $7,030,582,478 and the highest revenue forecast at $7,030,582,478.